Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,

Blood (2011) 118 (21): 3989.

https://doi.org/10.1182/blood.V118.21.3989.3989

Published: 2011

Journal Articles

Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols

Pingping Qu, Jeff Haessler, John Shaughnessy, Jr., PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 2985.

https://doi.org/10.1182/blood.V116.21.2985.2985

Published: 2010

Journal Articles

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

Blood (2009) 114 (22): 743.

https://doi.org/10.1182/blood.V114.22.743.743

Published: 2009

Journal Articles

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Michele H. Cottler-Fox, MD, Jeff Haessler, MD, Sarah Waheed, MD, Bijay Nair, MD, John Crowley, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3411.

https://doi.org/10.1182/blood.V114.22.3411.3411

Published: 2009

Journal Articles

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Twyla B. Bartel, Jeff Haessler, Tracy L. Y. Brown, John D. Shaughnessy, Jr, Frits van Rhee, Elias Anaissie, Terri Alpe, Edgardo Angtuaco, Ronald Walker, Joshua Epstein, John Crowley, Bart Barlogie

Blood (2009) 114 (10): 2068–2076.

https://doi.org/10.1182/blood-2009-03-213280

Published: 2009

Journal Articles

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

David C. Johnson, Sophie Corthals, Christine Ramos, Antje Hoering, Kim Cocks, Nicholas J. Dickens, Jeff Haessler, Harmut Goldschmidt, J. Anthony Child, Sue E. Bell, Graham Jackson, Dalsu Baris, S. Vincent Rajkumar, Faith E. Davies, Brian G. M. Durie, John Crowley, Pieter Sonneveld, Brian Van Ness, Gareth J. Morgan

Blood (2008) 112 (13): 4924–4934.

https://doi.org/10.1182/blood-2008-02-140434

Published: 2008

Includes: Supplemental data

Journal Articles

Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma

Brian G. Van Ness, PhD, Christine Ramos, Vipin Kumar, Michael Steinbach, Brian GM Durie, MD, John Crowley, PhD, Bart Barlogie, Antje Hoering, Jeff Haessler, David C Johnson, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 2715.

https://doi.org/10.1182/blood.V112.11.2715.2715

Published: 2008

Journal Articles

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

Bart Barlogie, MD, PhD, Elias J. Anaissie, MD, John D. Shaughnessy, Jr., PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, Jeff Haessler, MD, Klaus A. Hollmig, MD, Yazan Alsayed, MD, Sarah Waheed, MD, Monica Graziutti, MD, Elias Kiwan, MD, John Crowley, PhD

Blood (2008) 112 (11): 162.

https://doi.org/10.1182/blood.V112.11.162.162

Published: 2008

Journal Articles

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

Wei Xiong, Xiaosong Wu, Sarah Starnes, Sarah K. Johnson, Jeff Haessler, Siqing Wang, Lijuan Chen, Bart Barlogie, John D. Shaughnessy, Jr, Fenghuang Zhan

Blood (2008) 112 (10): 4235–4246.

https://doi.org/10.1182/blood-2007-10-119123

Published: 2008

Includes: Supplemental data

Journal Articles

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Jr, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, John Crowley

Blood (2008) 112 (8): 3115–3121.

https://doi.org/10.1182/blood-2008-03-145235

Published: 2008

Journal Articles

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Elias Anaissie, James Waldron, Mauricio Pineda-Roman, Raymond Thertulien, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, John Crowley, Jeffrey Sawyer

Blood (2008) 111 (1): 94–100.

https://doi.org/10.1182/blood-2007-06-097444

Published: 2008

Journal Articles

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Brian G.M. Durie, MD, Brian Van Ness, PhD, Christine Ramos, PhD, Owen Stephens, Majda Haznadar, Antje Hoering, PhD, Jeff Haessler, PhD, Michael S. Katz, BS, Gregory R. Mundy, MD, Robert A. Kyle, MD, Gareth J. Morgan, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, John Shaughnessy, Jr., PhD

Blood (2007) 110 (11): 816.

https://doi.org/10.1182/blood.V110.11.816.816

Published: 2007

Journal Articles

SNP Associations with Event Free Survival in Myeloma from Two Phase III Clinical Trials Using the Bank On A Cure Chip.

Brian G. Van Ness, PhD, John C. Crowley, Ph.D., Christine Ramos, B.S., Suzanne M. Grindle, Ph.D., Antje Hoering, Ph.D., Jeff Haessler, M.S., Susanna Jacobus, M.S., Brian G. Durie, MD, Michael Katz, Ph.D., Vincent S. Rajkumar, MD, Bart Barlogie, MD, David C. Johnson, Ph.D., Gareth J. Morgan, MD

Blood (2006) 108 (11): 131.

https://doi.org/10.1182/blood.V108.11.131.131

Published: 2006

Journal Articles

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Gareth J. Morgan, MD, PhD, David C. Johnson, BSc, John Crowley, PhD, John Shaughnessy, Jr., PhD, Pieter Sonneveld, MD, Brian Durie, MD, Christine Ramos, PhD, Brian G. Van Ness, PhD, Bart Barlogie, MD, Antje Hoering, PhD, Jeff Haessler, PhD, Dalsu Baris, MD, PhD, Michael Katz, BS, Vincent S. Rajkumar, MD, H. Goldschmidt, MD

Blood (2006) 108 (11): 246.

https://doi.org/10.1182/blood.V108.11.246.246

Published: 2006

Journal Articles

Lack of Predictive Value of KIR-HLA Genotypes for Autologous Transplant Outcome for Multiple Myeloma.

Katharine C. Hsu, MD, PhD, Guido Tricot, MD PhD, Jeff Haessler, PhD, Clara Pinto-Agnello, MS, Frits van Rhee, MD PhD, Michelle Fox, MD, Bo Dupont, MD DSc

Blood (2006) 108 (11): 3078.

https://doi.org/10.1182/blood.V108.11.3078.3078

Published: 2006

NARROW

Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,

Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Analytical Approaches for the BOAC SNP Panel Association with Progression Free Survival in Myeloma

Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

SNP Associations with Event Free Survival in Myeloma from Two Phase III Clinical Trials Using the Bank On A Cure Chip.

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Lack of Predictive Value of KIR-HLA Genotypes for Autologous Transplant Outcome for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only